| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ChemoCentryx, Mountain View, CA 94043
Although chemokines CCL3/MIP-1
and CCL5/RANTES are considered to be primary CCR1 ligands in inflammatory responses, alternative CCR1 ligands have also been described. Indeed, four such chemokines, CCL6/C10/MIP-related protein-1, CCL9/MIP-1
/MIP-related protein-2, CCL15/MIP-1
/hemofiltrate CC chemokine-2/leukotactin-1, and CCL23/CK
8/myeloid progenitor inhibitory factor-1, are unique in possessing a separately encoded N-terminal domain of 16–20 residues and two additional precisely positioned cysteines that form a third disulfide bridge. In vitro, these four chemokines are weak CCR1 agonists, but potency can be increased up to 1000-fold by engineered or expression-associated N-terminal truncations. We examined the ability of proinflammatory proteases, human cell supernatants, or physiological fluids to perform N-terminal truncations of these chemokines and thereby activate their functions. Remarkably, most of the proteases and fluids removed the N-terminal domains from all four chemokines, but were relatively unable to cleave the truncated forms further. The truncated chemokines exhibited up to 1000-fold increases in CCR1-mediated signaling and chemotaxis assays in vitro. In addition, N-terminally truncated CCL15/MIP-1 and CCL23/CK8, but not CCL3/MIP-1 or CCL5/RANTES, were detected at relatively high levels in synovial fluids from rheumatoid arthritis patients. These data suggest that alternative CCR1 ligands are converted into potent chemoattractants by proteases released during inflammatory responses in vivo.
This article has been cited by other articles:
|
|
 |
|
  B. Savino, E. M. Borroni, N. M. Torres, P. Proost, S. Struyf, A. Mortier, A. Mantovani, M. Locati, and R. Bonecchi Recognition Versus Adaptive Up-regulation and Degradation of CC Chemokines by the Chemokine Decoy Receptor D6 Are Determined by Their N-terminal Sequence J. Biol. Chem., September 18, 2009; 284(38): 26207 - 26215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Tausch, A. Henkel, U. Siemoneit, D. Poeckel, N. Kather, L. Franke, B. Hofmann, G. Schneider, C. Angioni, G. Geisslinger, et al. Identification of Human Cathepsin G As a Functional Target of Boswellic Acids from the Anti-Inflammatory Remedy Frankincense J. Immunol., September 1, 2009; 183(5): 3433 - 3442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Camateros, C. Kanagaratham, J. Henri, R. Sladek, T. J. Hudson, and D. Radzioch Modulation of the allergic asthma transcriptome following resiquimod treatment Physiol Genomics, August 7, 2009; 38(3): 303 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vojdani and J. Lambert The Role of Th17 in Neuroimmune Disorders: Target for CAM Therapy. Part I Evid. Based Complement. Altern. Med., July 21, 2009; (2009) nep062v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Magnusson, G. Pejler, S. Kleinau, and M. Abrink Mast cell chymase contributes to the antibody response and the severity of autoimmune arthritis FASEB J, March 1, 2009; 23(3): 875 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Miao, B. A. Premack, Z. Wei, Y. Wang, C. Gerard, H. Showell, M. Howard, T. J. Schall, and R. Berahovich Proinflammatory Proteases Liberate a Discrete High-Affinity Functional FPRL1 (CCR12) Ligand from CCL23 J. Immunol., June 1, 2007; 178(11): 7395 - 7404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Shimoda, N. Fukazawa, K. Nonomura, and R. L. Fairchild Cathepsin G Is Required for Sustained Inflammation and Tissue Injury after Reperfusion of Ischemic Kidneys Am. J. Pathol., March 1, 2007; 170(3): 930 - 940. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
